Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $9.52, but opened at $8.73. Dyne Therapeutics shares last traded at $9.16, with a volume of 2,817,287 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Robert W. Baird dropped their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. HC Wainwright dropped their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Scotiabank initiated coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target on the stock. Jones Trading assumed coverage on Dyne Therapeutics in a report on Thursday, June 26th. They issued a "buy" rating and a $30.00 price objective for the company. Finally, Evercore ISI began coverage on shares of Dyne Therapeutics in a report on Thursday, May 29th. They set an "outperform" rating and a $46.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $41.13.

Dyne Therapeutics Stock Up 1.2%

The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -2.52 and a beta of 1.08. The company's 50 day simple moving average is $11.73 and its two-hundred day simple moving average is $13.47.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. Bank of New York Mellon Corp increased its holdings in shares of Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after acquiring an additional 698 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Dyne Therapeutics by 2.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 667,452 shares of the company's stock worth $15,725,000 after purchasing an additional 18,800 shares during the last quarter. Victory Capital Management Inc. grew its position in Dyne Therapeutics by 100.9% during the 4th quarter. Victory Capital Management Inc. now owns 61,348 shares of the company's stock worth $1,445,000 after purchasing an additional 30,811 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Dyne Therapeutics during the 4th quarter valued at approximately $2,340,000. Finally, Candriam S.C.A. raised its holdings in shares of Dyne Therapeutics by 2.7% in the fourth quarter. Candriam S.C.A. now owns 401,395 shares of the company's stock worth $9,457,000 after buying an additional 10,439 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.